THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...
As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...
--Amgen today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ®, that add to the growing body of ...
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results